Showing results (81-90 of 95) with videos related to
Sort By:
Pageof 10
The Journal of Biological Chemistry|October 15, 2017
A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-IKelly A Manthei, Joomi Ahn, Alisa Glukhova, et al.Journal of Inherited Metabolic Disease|March 26, 2010
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapyJohn Marshall, Kerry Anne McEachern, Wei-Lien Chuang, et al.Plos One|December 3, 2010
Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseaseJohn Marshall, Karen M Ashe, Dinesh Bangari, et al.Plos One|June 25, 2010
Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthaseNelson S Yew, Hongmei Zhao, Eun-Gyoung Hong, et al.Journal of Virology|February 27, 2009
Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine norovirusesStefan Taube, Jeffrey W Perry, Kristen Yetming, et al.Journal of Lipid Research|December 25, 2007
Ceramide kinase promotes Ca2+ signaling near IgG-opsonized targets and enhances phagolysosomal fusion in COS-1 cellsVania Hinkovska-Galcheva, Andrea Clark, Susan VanWay, et al.The Journal of Biological Chemistry|March 16, 2011
Lowering glycosphingolipid levels in CD4+ T cells attenuates T cell receptor signaling, cytokine production, and differentiation to the Th17 lineageYunxiang Zhu, Nathan Gumlaw, Jozsef Karman, et al.Molecular Genetics and Metabolism|May 19, 2007
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseKerry Anne McEachern, John Fung, Svetlana Komarnitsky, et al.Hepatology (Baltimore, Md.)|May 16, 2009
Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese miceHongmei Zhao, Malgorzata Przybylska, I-Huan Wu, et al.ACS Chemical Neuroscience|October 9, 2020
Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3Michael W Wilson, Liming Shu, Vania Hinkovska-Galcheva, et al.Pageof 10